A whirlwind of excitement these past couple of days! I am deeply honored and humbled to receive this
@HHMINEWS
recognition and award. Big thanks to all
@kadochlab
@DanaFarber
members, past and present, who have made this possible! To the next 7 years and beyond!
#science
🙏🙏
HHMI News: We are proud to announce our 33 new
#HHMIInvestigators
. These individuals have the potential to make transformative discoveries over time and we look forward to seeing where their ideas lead them.
Thank you
@MSKCancerCenter
for this incredible honor of the 2023 Paul Marks Prize! I am grateful to receive this alongside two other brilliant investigators and friends. My teams will continue on our mission to advance novel biology to new medicines for patients with
#cancer
.
Congratulations to this year’s recipients of the 2023 Paul Marks Prize for Cancer Research: Dr. Mark Agnel Frederick Dawson, Dr. Cigall Kadoch, and Dr. Michelle Monje-Deisseroth. Read more:
Thank you,
@sciencemagazine
for this wonderful honor- I look forward to delivering the award lecture at the
@NIH
next month! And most importantly, congrats to all
@kadochlab
members - it is their brilliant work that is being recognized.
Congratulations to Cigall Kadoch (
@ckadoch
,
@kadochlab
) from
@DanaFarber
on winning this year’s AAAS Martin and Rose Wachtel Cancer Research Award for her work on chromatin remodeling in cancer.
@ScienceTM
Extremely honored and humbled today to be named a Blavatnik National Awards finalist among these talented peers. My laboratory members and I look forward to many productive and exciting years to come!
@BlavatnikAwards
@DanaFarberNews
@broadinstitute
@harvardmed
Thrilled and honored to have had the opportunity to ring the
@Nasdaq
opening bell this morning in Times Square, in celebration of
@foghorntx
, Inc going public! 🎉🎉
#FHTX
#FoghornTxIPO
! Here’s to all that lies ahead in delivering new, first-in-class medicines to patients.
Welcome to the
@Nasdaq
family,
@Foghorntx
! 👏👏👏
Foghorn Therapeutics,
#NasdaqListed
as $FHTX, is discovering and developing an unprecedented class of medicines using their proprietary Gene Traffic Control™ Product Platform.
#FoghornTxIPO
Huge congratulations,
@kadochlab
and our Walz, DiMaio, Ranish, Roeder and He lab collaborators on a job well done! Great to see this 5+ year effort published!
@NMashtalir
@akshaysci
Huge congratulations to my talented graduate student,
@FreddyMValencia
and our colleagues in the
@kadochlab
,
@Muirlab
and
@DanaFarber
! Exciting new paper on a critical interface between the human mSWI/SNF (BAF) chromatin remodeling complex and nucleosomes that governs activity.
New Article online now at Cell: Recurrent SMARCB1 Mutations Reveal a Nucleosome Acidic Patch Interaction Site That Potentiates mSWI/SNF Complex Chromatin Remodeling
A major milestone for
@foghorntx
(NASDAQ: FHTX) and our field at-large in dosing the first patient with a new class of small molecules targeting chromatin remodeling complexes. FHD-268 targets the BRG1/BRM ATPases of the mSWI/SNF complexes. Grateful to our team and patients.
Today, we announced the first patient was dosed in our FHD-286
#clinicaltrial
, a key milestone in our mission to change the lives of those with serious diseases. This is the first candidate from a new drug class targeting the
#chromatin
regulatory system:
Congratulations to Cigall Kadoch (
@ckadoch
,
@kadochlab
) from
@DanaFarber
on winning this year’s AAAS Martin and Rose Wachtel Cancer Research Award for her work on chromatin remodeling in cancer.
@ScienceTM
Congratulations to
@DanaFarber
’s Cigall Kadoch, PhD, and Eric S. Fischer, PhD, finalists for the 2023 Blavatnik National Awards for Young Scientists which honor outstanding scientists and engineers under the age of 42.
@blavatnikawards
@NYASciences
Congratulations,
@kadochlab
on a major study unraveling the modular organization and assembly of mSWI/SNF chromatin remodeling complexes- new views in to disease mechanisms!
A great pleasure to Chair and speak in the
#AACR24
@AACR
Major Symposium on
#Epigenetics
and Chromatin Regulation in Cancer! Packed house, exciting science, and fantastic presentations by my two colleagues and friends,
@Yael_David__
and
@ArulChinnaiyan
!
Very excited to share that the second major program at
@foghorntx
, FHD-609, is now in the clinic! This one hits extra close to home as our initial studies in
#synovial
#sarcoma
are what catalyzed a new understanding of the large class of cancers and other diseases driven by BAF.
Today, we announced the first patient was dosed in our
#clinicaltrial
for FHD-609, being developed for the treatment of
#synovialsarcoma
. This important milestone marks our first protein degrader & second pipeline candidate to enter the clinic: $FHTX
A moving evening to celebrate 4 decades of science for legend Stu Orkin earlier this week. Stu hired me to
@DanaFarber
@BostonChildrens
and I have been ever inspired by his commitment to basic science toward discoveries that will benefit many. Bravo and thank you, Stu!
A big thank you to everyone for the tweets, emails and messages about the
@aaas
Wachtel Prize- I am very grateful to receive this honor and look forward to all that the
@kadochlab
has in store in the coming years!
Eli Lilly's Jake Van Naarden uncorked a deal to provide Flagship-backed Foghorn Therapeutics $380 million — $300 million in cash and $80 million for a premium equity deal — to jump on board the biotech’s development platform.
Join us in congratulating the 2021 Excellence in Science Award recipients: Celeste Simon
@PennMedicine
, Valentina Greco
@YaleMed
, and Cigall Kadoch
@harvardmed
! Read more:
Thank you for the tremendous support of and investment in our laboratory,
@HHMINEWS
, which has been and continues to be instrumental for our progress!
Excited to advance our work with Cancer Grand Challenge
@CR_UK
@CancerGrand
as part of Team PROTECT to address major challenges in treating children with cancer. A major signal to the world in London today with not 1 but 2 (!) newly announced teams focused on
#pediatric
#cancer
!
📢 Announcing five new global
#CancerGrandChallenges
teams! 📢
We're thrilled to announce five new teams, each receiving up to $25m over five years to tackle some of cancer's toughest challenges.
Meet the teams:
@CR_UK
@theNCI
Exciting new results from our
@kadochlab
with the Politi lab at Yale highlighting the utility of mSWI/SNF
#BAFcomplex
ATPase inhibitors in reversing kinase inhibitor
#drugresistance
in
#EGFR
-mutant
#lung
#cancers
. Congrats to the team on this timely and impactful study!
Thank you to all of my colleagues, collaborators, and the leadership of
@DanaFarber
@DanaFarberNews
for the unwavering support for all of our research efforts over the past nearly decade now in
#Boston
. Our
@kadochlab
is most fortunate to call DFCI our home!
Congratulations to
@DanaFarber
's Cigall Kadoch, PhD, (
@CKadoch
) who was named as the Laureate of the Blavatnik National Awards for Young Scientists today. The prestigious award from
@BlavatnikAwards
and
@NYASciences
(cont)
Thank you,
@broadinstitute
and
@IndraniMk
for profiling our work
@kadochlab
@DanaFarber
! I am fortunate to work alongside such a talented, creative, kind, and dedicated group of people each day, and am excited about all we have to come! This journey is just beginning.
A 2013 discovery by
@CKadoch
linking mutations in a cellular machine called BAF to cancer was the start of a journey for
@kadochlab
@danafarber
. Read about that journey of discovery finding BAF-related disease mechanisms and therapeutic opportunities:
Thrilled that this exciting paper is now out! Really amazing work by
@ajinkyapatil00
in
@CKadoch
lab &
@DNAmyStrom
in our lab w/ great collaborators including
@PappulabWashU
. One of the most important papers ever in the biomolecular condensate field!!!
Congratulations to
@DanaFarber
's Rosalind Segal, Benjamin Ebert, Cigall Kadoch, Eric Fischer, Kimberly Stegmaier and Scott Armstrong on being shortlisted for the next
@CancerGrand
Challenges awards! (Photo by Ken Richardson Photo)
#CancerGrandChallenges
Congratulations to ASBMB member
@CKadoch
on receiving the 2020
@AACR
Award for Outstanding Achievement in Basic Cancer Research, which recognizes achievements in basic research into
#cancer
by faculty 45 years old or younger.
Exciting to see our
@kadochlab
and
@Oser_Lab
collaborative study focused on mSWI/SNF chromatin remodeling complexes in small cell lung cancer out in
@Cancer_Cell
! This is one of 4+ studies published/soon to be published highlighting the potential for
#BAF
disruption in SCLC!
(Far left) Cigall Kadoch, PhD, (
@CKadoch
) of
@DanaFarber
is a recipient of this year’s
@MSKCancerCenter
Paul Marks Prize for Cancer Research presented biennially to cancer research leaders under 50 who are making significant contributions.
Chromatin-targeted drug discovery at “a very special moment”
Cigall Kadoch, a researcher at Dana-Farber Cancer Institute & co-founder of Foghorn Therapeutics, discusses the case for a new wave of epigenetic drugs targeting chromatin remodelling complexes
Thank you
@nyugrossman
for having me today in NYC, and especially to
@KJArmache
for being an incredible host! A day of great scientific meetings and wonderful to see many colleagues and friends, including
@iannisaifantis1
!
Presentation of our work in developing a novel SS18-SSX fusion- specific antibody! Collaboration between
@mcbride_matthew
of
@kadochlab
, Esther Baranov and Jason Hornick of BWH
@BrighamWomens
, and
@CellSignal
! Congrats to all— Publication coming....
Don’t miss Dr. Baranov of
@brighamwomens
Dept of Pathology speaking at
#USCAP2020
Mar 2 @ 11am on A Novel SS18-SSX Fusion-Specific Antibody for the Diagnosis of Synovial Sarcoma.
#antibody
Cigall Kadoch has won the 2019 AAAS Martin and Rose Wachtel Cancer Research Award for her innovative work revealing how mutations in
#chromatin
remodeling machines drive rare forms of cancer. Congratulations!
@CKadoch
Congrats to Cigall Kadoch, co-founder of
@foghorntx
, on being named a finalist for the 2023 Blavatnik National Awards in the life sciences. Tune in to a chat from Flagship’s 2023 Women in Science event to hear more from Cigall about her career:
We're pleased to announce that our BRM selective inhibitor, in partnership with Lilly, is moving into the clinic. Learn more about the news and our primary development plans to target BRG1 mutated non-small cell lung
#cancer
(NSCLC):
We enjoyed today the fantastic research presented by
@CKadoch
@kadochlab
@DanaFarber
sharing their latest on chromatin remodeling complexes deregulation in human disease. So Inspiring! Thank you for visiting and delivering this lectureship
@MayoClinic
So happy for our outstanding graduate student,
@whit_lieberman
who has been awarded the NIH F31 fellowship to support her new work on chromatin remodelers in the lab! An honor to watch your success and excited for all that you will accomplish, Whitney!
@NIH
@chemical_phd
Congratulations to
@whit_lieberman
in our lab who had just been officially awarded an NIH F31 fellowship to support her exciting graduate studies! We are thrilled!!
@kadochlab
@chemical_phd
Great chromatin conference in Spetses, Greece last week- fantastic talks and dinners with students, thanks to A. Ladurner and
@MarcusBuschbeck
@ChroMeITN
!!
@kadochlab
attendance next time!
Congratulations, Dr.
@ajinkyapatil00
on your official graduation from
@harvardmed
and an honor to hood you and meet your family!! So many amazing achievements in your PhD! And thrilled to watch past
@kadochlab
member Dr.
@JohnPulice
also walk across the stage! Congratulations!!!
It was terrific to participate in the
@NIH
RADAR Workshop on Biomolecular Condensates these past two days. Great to see these good friends and colleagues as well as to meet many new investigators.
Congrats to
@proodolph
, Clayton Collings and all co-authors on this recent publication in
@NatureGenet
!
#cBAF
compromise via SMARCE1 loss in clear cell
#meningioma
(CCM) -->increased assembly and function of
#ncBAF
complexes, leading to CCM-specific oncogenic gene expression.1/2
Do you know how Foghorn Therapeutics was founded? Dive into the visionary journey of our company with our founder,
@CKadoch
, and hear her story behind the inception of Foghorn and the groundbreaking science to modulate the chromatin regulatory system:
Congratulations,
@joshbiology
on your amazing thesis defense today! The whole
@kadochlab
@harvardmed
is so proud of you and can’t wait to see your exciting studies in print soon!!
A new study co-led by
@CKadoch
shows that her years of work exploring mSWI/SNF complexes that led to experimental cancer therapies also show promising use against COVID-19 by inhibiting a wide range of COVID variants.
Congratulations to Dr. Cigall Kadoch (
@CKadoch
) on being named a
@HHMINEWS
Investigator, one of the most prestigious honors in science. This support will enable
@kadochlab
to continue its quest for discoveries in cancer research.
Ludwig
@Harvardmed
’s
@CKadoch
chaired a symposium and presented her lab’s latest findings at
#AACR24
on the role of chromatin remodeling complexes in cancer maintenance and drug resistance and the latest on targeting of these protein machines for cancer therapy.
Thank you,
@UCDavisHealth
@UCD_Cancer
for the honor to give the Distinguished Lecture in Cancer Research yesterday! Great to see the tremendous growth of the institution over the past several years! Thank you for hosting,
@RLRandallMD
, and great to see you,
@PrimoLaraMD
A big congratulations to
@joshbiology
on your graduation!!! I am so honored to have had you as my first Ph.D. student and humbled to have this opportunity to hood you! So many wonderful things you will do in your life!!
@harvardmed
@kadochlab
On Sept. 24th at 12:00 pm ET,
@CKadoch
@DanaFarber
will share her
#FusOnC2
research focusing on the structure and function of SWI/SNF complexes in synovial sarcoma at the
#CancerMoonshot
Seminar Series. Learn more:
Extremely excited for all the key milestones and beyond at Foghorn Therapeutics
@foghorntx
in 2023– We will continue to take leaps toward our goal of helping millions of patients fighting devastating diagnoses of cancer and other diseases.
#cancer
#chromatin
#drug
#discovery
#JPM23
During
#JPM23
, our CEO Adrian Gottschalk shared why he’s excited for 2023 with
@FlagshipPioneer
, highlighting our upcoming milestones & the prolific nature of our platform to target the chromatin regulatory system to develop precision therapies in oncology & beyond.
#FlagshipJPM
Exciting news!
@foghorntx
announced the start of their first human clinical trial, testing their novel BRG1/BRM inhibitor as a treatment for metastatic uveal melanoma (and AML). Congratulations
@CKadoch
and colleagues!
The Kadoch Lab studies the role of ATP-dependent chromatin remodeling complexes in gene regulation and disease. Our favorite remodeler is the BAF complex—what’s yours?
3/n